IDEAYA Biosciences, Inc. (IDYA) Reaffirms Cash Runway Into 2030

What happened

IDEAYA Biosciences reported a third-quarter 2026 net loss of $125.7 million, up from $112.5 million in the prior quarter. Cash and marketable securities fell to approximately $1.15 billion at September 30 from $1.24 billion at June 30, while its cash-runway guidance into 2030 remained unchanged.

Confirmed

Global impact / market context

The unchanged runway guidance suggests IDEAYA expects its available cash to support operations into 2030 despite a wider quarterly loss and lower cash reserves. Continued spending on development and commercial preparation could reduce cash further, making future cash use and progress on its drug program important to that outlook.

Analyst inference

This is a quarterly financial update for a clinical-stage oncology company, whose products are still in development. Collaboration revenue rose to $10.2 million from $8.9 million, primarily from services under the Servier darovasertib license agreement, but the reported loss indicates spending exceeded revenue.

Confirmed

What to watch

1. Compare future cash balances and quarterly losses with the stated runway into 2030; faster cash use could make that funding horizon harder to maintain. Analyst inference
2. Watch for FDA review developments for the darovasertib NDA, a regulatory application seeking approval, which the supplied context identifies as relevant to assessing the runway outlook. Confirmed
3. Track whether collaboration revenue from services under the Servier darovasertib agreement continues to rise, since recurring revenue could help offset development and preparation costs. Analyst inference

Evidence

• Original source link unavailable